Market Cap: $277.23B
Market Cap: $277.23B
Open
$189.34
Prev. Close
$182.27
High
$189.80
Low
$186.25
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas.
AstraZeneca PLC trades on the New York Stock Exchange under the ticker AZN, priced in USD.
AstraZeneca PLC has a market capitalisation of $277.23B, based on its latest share price.
AZN trades at 25.31 times its trailing 12-month earnings.
Over the past 52 weeks AZN has traded between $153.41 and $212.71.
Yes. AstraZeneca PLC's dividend yields 1.87% at the current share price, paying out 47% of its earnings.
Highly profitable: keeps 17.0% of revenue as net profit.
The analyst consensus rating for AZN is Buy. Analysts' average 12-month price target of $211.00 implies 18% upside.
Pascal Claude Roland Soriot is the CEO of AstraZeneca PLC, which is headquartered in Cambridge.
Generated automatically from reported financial data. General information only, not financial advice.

AstraZeneca PLC ( AZN ) is navigating a multifaceted landscape marked by both challenges and growth opportunities. The company's recent performance highlights a robust strategy aimed at overcoming obs…

AstraZeneca PLC ( AZN ) is at the forefront of transformative developments that could reshape its presence in the global pharmaceutical landscape. Current reports indicate that AstraZeneca is in talks…

AstraZeneca PLC AZN is navigating a challenging landscape as it seeks to maintain its reputation for innovative drug development and aggressive growth targets. This comes in the wake of recent setback…

Astrazeneca plc (Ticker: AZN) partners with ZERO Prostate Cancer on a transformative initiative aimed at improving prostate cancer care. Joining Forces to Combat Disparities The Blitz the Barriers pro…